Shandong Wohua Pharmaceutical Co.Ltd(002107)
Annual report 2021
January 2022
Section I important tips, contents and definitions
The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee that the contents of the annual report are true, accurate and complete without false records, misleading statements or major omissions, and bear individual and joint legal liabilities.
Zhao Bingxian, the person in charge of the company, Wang Jiong, the person in charge of accounting, and Wang Jiong, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in this annual report.
All directors have attended the board meeting to consider this report.
The future development statement involved in this report is a planned event and does not constitute the company’s substantive commitment to investors. Please pay attention to investment risks.
In Section III “management discussion and analysis” of this report, “Xi. Prospect of the company’s future development” describes in detail the possible risks in the company’s operation. Please pay attention to the relevant contents. The profit distribution plan approved by the board of directors is: take 577209600 shares as the base, distribute cash dividends of 2.60 yuan (including tax) to all shareholders for every 10 shares, send bonus shares of 0 shares (including tax), and do not use accumulation fund to increase share capital.
catalogue
Section I important tips, contents and definitions Section 2 company profile and main financial indicators Section III Management Discussion and Analysis Section 4 corporate governance Section V environmental and social responsibility 81 section VI important matters Section VII changes in shares and shareholders 96 Section VIII preferred shares 101 section IX information related to bonds 102 section x financial report one hundred and three
Directory of documents for future reference
1、 Financial statements signed and sealed by the legal representative, the person in charge of accounting and the person in charge of accounting institutions. 2、 The original of the audit report with the seal of the accounting firm and the signature and seal of the certified public accountant. 3、 The originals of all company documents and announcements publicly disclosed by the information disclosure media designated by the CSRC during the reporting period. 4、 The original copy of the company’s 2021 annual report signed by the legal representative. 5、 The place where the above documents for future reference are prepared: the office of the board of directors of the company and Shenzhen Stock Exchange.
interpretation
Explanatory item refers to the explanatory content
The company, the company and Shandong Wohua Pharmaceutical Co.Ltd(002107) refer to Shandong Wohua Pharmaceutical Co.Ltd(002107)
Nanchang Jishun refers to Nanchang Jishun Pharmaceutical Co., Ltd
Liaoning wohua Kangchen refers to Liaoning wohua Kangchen Pharmaceutical Co., Ltd
GMP refers to the good manufacturing practice
Board of directors means the Shandong Wohua Pharmaceutical Co.Ltd(002107) board of directors
Executive Committee / Executive Committee of the board of directors refers to the Executive Committee of Shandong Wohua Pharmaceutical Co.Ltd(002107) board of directors
Board of supervisors means the Shandong Wohua Pharmaceutical Co.Ltd(002107) board of supervisors
General meeting means Shandong Wohua Pharmaceutical Co.Ltd(002107) general meeting of shareholders
The reporting period refers to the period from January 1, 2021 to December 31, 2021
Four exclusive healthcare pillar products refer to wohua ® Xinkeshu tablet, Gushukang capsule / granule, Hedan tablet / capsule, Naoxueshu oral liquid
National health commission refers to the National Health Commission
National Medical Insurance Bureau refers to the National Medical Security Bureau
The State Drug Administration refers to the State Drug Administration
Diagnosis related groups refers to the grouping of inpatients according to the similarity of disease severity, complexity of treatment methods and resource consumption. DRG refers to a certain number of disease groups, covering all acute inpatients in principle, The factors that determine the enrollment of patients include the main diagnosis, main treatment methods, complications, age, length of hospital stay and so on.
Diagnosis intervention packet, which is paid according to the score of disease type, refers to the exhaustive and clustering of “disease diagnosis + treatment” dip of each case based on historical data and realistic matching relationship, so as to combine stable inpatient diseases, According to the proportional relationship between the average cost of each disease, technical difficulty, etc. and a benchmark disease, determine the corresponding disease points, and then calculate the total payment amount in combination with the point unit price and the total points carried out by each medical institution, Medical insurance is the method of payment to medical institutions.
Section II Company Profile and main financial indicators
1、 Company information
Stock abbreviation Shandong Wohua Pharmaceutical Co.Ltd(002107) stock code 002107
Shenzhen Stock Exchange
Chinese name of the company Shandong Wohua Pharmaceutical Co.Ltd(002107)
Chinese abbreviation of the company Shandong Wohua Pharmaceutical Co.Ltd(002107)
Foreign name of the company (if any) Shandong wohua Pharmaceutical Co., Ltd
Legal representative of the company: Zhao Bingxian
Registered address: No. 3517, Liyuan street, Weifang High tech Industrial Development Zone, Shandong Province
Postal code of registered address 261205
There is no historical change of the company’s registered address
Office address: No. 3517, Liyuan street, Weifang High tech Industrial Development Zone, Shandong Province
Postal code of office address 261205
Company website http://www.wohua.cn.
E-mail [email protected].
2、 Contact person and contact information
Secretary of the board of directors and securities affairs representative
Name: Zhao Caixia
Contact address: Liyuan, Weifang High tech Industrial Development Zone, Shandong Province
3517 St
Tel: 0536-8553373
Fax 0536-8553373
E-mail [email protected].
3、 Information disclosure and preparation location
The website of the stock exchange where the company discloses the annual report http://www.szse.cn.
The media name and website of the annual report disclosed by the company are China Securities Journal, securities times http://www.cn.info.com.cn.
The company’s annual report is prepared at the office of the board of directors and Shenzhen Stock Exchange
4、 Registration change
No change in organization code
Whether the changes of the company’s main business (if any) have changed since its listing
No change of previous controlling shareholders (if any)
5、 Other relevant information: accounting firm employed by the company
Name of accounting firm: YONGTUO accounting firm (special general partnership)
Office address of the accounting firm: 13 / F, building 2, No. 1, guandongdian North Street, Chaoyang District, Beijing
Name of signature accountant: Jing Xiumei, Hou Zengyu
Recommendation agencies hired by the company to perform continuous supervision duties during the reporting period □ applicable √ not applicable to financial consultants hired by the company to perform continuous supervision duties during the reporting period □ applicable √ not applicable VI. major accounting data and financial indicators whether the company needs to retroactively adjust or restate the accounting data of previous years □ yes √ no
2021-2020 year-on-year increase or decrease 2019
Operating income (yuan) 942674553.55 1006081515.18 – 6.30% 860290535.41
Net profit attributable to shareholders of listed company
(yuan) 163392002.72 178880358.04 – 8.66% 95801508.50
Deduction attributable to shareholders of listed companies
Net profit of recurring profit and loss (yuan) 15732813.26 168985174.22 – 6.90% 90025394.46
Net cash flow from operating activities
(yuan) 200119233.17 1965 77975.59 1.80% 31655284.93
Basic earnings per share (yuan / share) 0.28 0.31 – 9.68% 0.17
Diluted earnings per share (yuan / share) 0.28 0.31 – 9.68% 0.17
Weighted average return on net assets: 20.71%, 24.18% – 3.47%, 15.21%
